Observation of the Short-term Efficacy of Technetium-99 Conjugated with Methylene Diphosphonate Combined Therapy in the Treatment of Postmenopausal Osteoporosis.

What Was Tested

The paper reports a study of Methylene blue (non-peptide stack partner), published as a randomized controlled trial.

Who Took Part

According to the abstract, 112 patients were involved.

The age groups tagged for this paper are middle-aged adults and older adults, women only.

A total of 112 patients with PMOP who received treatment in the Department of Nuclear Medicine of the hospital from January 2019 to June 2020 were selected and randomly divided into 4 groups of 28 patients each.

How the Study Was Run

The researchers set it up as a randomized study.

Random assignment meant chance, not the researchers, decided who got Methylene blue (non-peptide stack partner) and who got the comparison, which limits bias.

Group A received Yunke and PEMFs, group B received Gukang capsules and PEMFs, group C received Yunke and Gukang capsules and PEMFs, and group D received PEMFs.

All groups were given adequate amounts of calcium and active vitamin D.

Intervention 2 sessions of 3 months each.

What Was Measured

The subject headings attached to it are Osteoporosis, Postmenopausal, Bone Density, Technetium Tc 99m Medronate, Bone Density Conservation Agents and Radiopharmaceuticals.

Author keywords: Postmenopausal osteoporosis, bone mineral density, femoral neck, gukang capsule, pulsed electromagnetic fields and yunke.

What This Means in Plain Language

The paper is a randomized study of Methylene blue (non-peptide stack partner) in 112 patients.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2024 (Combinatorial chemistry & high throughput screening), a journal based in United Arab Emirates.

More context: the Methylene blue (non-peptide stack partner) compound page, all human trials.